A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B

Table 1 Baseline characteristics of patients

	Group A	Group B	Group C
Characteristics	(LVD, 100 mg/d)	(ETV, 0.5 mg/d)	(ETV, 1.0 mg/d)
Patients (n)	21	21	19
Age ( yr)	31 ± 12	33 ± 10	31 ± 11
Sex ( M/F )	11/10	12/9	11/8
HBV DNA (log copies/mL)	8.49 ± 1.10	8.52 ± 1.02	8.60 ± 0.90
ALT (IU/L)	201.6 ± 178.2	211.2 ± 144.7	198.9 ± 169.5

P value was not significant for all comparisons. ALT: alanine aminotransferase.

Table 2 Adverse events documented during treatment

Adverse events	Group A	Group B	Group C
Patients (n)	21	21	19
Headache	7	6	7
Upper respiratory tract infection	3	3	4
Nasopharyngitis	4	3	4
Cough	2	2	1
Pyrexia	3	3	4
Upper abdominal pain	2	2	1
Fatigue	5	6	5
Diarrhea	7	6	6
Death	0	0	0
ALT > 2 × baseline > and 10 × ULN	4	1	2

ALT: alanine aminotransferase; ULN: upper limit of normal.